Cranbury, New Jersey-based Rafael Pharmaceuticals reported disappointing results from two Phase III clinical trials evaluating the safety and efficacy of the cancer metabolism drug CPI-613 (devimistat) when combined with modified FOLFIRINOX (mFFX) as a first-line therapy.
If you are not happy with the results below please do another search
50 search results for:
Texas A&M University Science Center, MD Anderson Cancer Center, and Pulmotect report that the drug PUL-042 appears to work against COVID-19 and other respiratory infections.
An estimated 30 million to 50 million doses of Johnson & Johnson’s Covid-19 vaccine are sitting idly in Emergent BioSolutions’ Baltimore facility waiting to be distributed.
In the company’s third-quarter 2021 financial earnings report, Novartis noted that the Swiss drugmaker is the subject of a U.S. Department of Justice (DOJ) inquiry over the marketing and pricing of Entresto during the past five years, receiving a Civil Investigative Demand from the government.
Merck & Co. Inc. on Oct. 28 said the company’s experimental Covid-19 drug could bring in between $5 billion and $7 billion in sales through the end of 2022, assuming the antiviral drug molnupiravir gains U.S. authorization in December 2021.
The World Health Organization (WHO) and other aid groups on Oct. 28 appealed to leaders of the world’s 20 biggest economies to fund a $23.4 billion plan to bring Covid-19 vaccines, tests and drugs to poorer countries in the next year.
The Ad Council, America’s leading non-profit organization dedicated to using the power of communications to drive social change, elected 18 new members to the Board of Directors during its fall meeting held virtually October 27.
Four years after partnering with GammaDelta Therapeutics to develop therapies for solid tumors, Takeda Pharmaceutical pulled the trigger and exercised its option to acquire the London-based company.
An advisory panel of the U.S. Centers for Disease Control and Prevention will meet on Nov. 2 to discuss the use of Covid-19 vaccines in children aged between 5 and 11 years.
A new study shows the persistent syndrome of Covid-19 after-effects known as long Covid can develop after “breakthrough” infections in vaccinated people. Other new findings suggest a gene that helps the coronavirus reproduce itself might contribute to life-threatening Covid-19 in young, otherwise healthy people.